What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Breast cancer
Breast cancer, Internal medicine, Oncology, Metastatic breast cancer and Surgery are his primary areas of study.
Breast cancer is a subfield of Cancer that Andreas Schneeweiss tackles.
His is involved in several facets of Internal medicine study, as is seen by his studies on Chemotherapy, Docetaxel, Hazard ratio, Taxane and Trastuzumab.
He combines subjects such as Neoadjuvant therapy, Anthracycline, Carboplatin, Pathology and Pertuzumab with his study of Oncology.
The concepts of his Metastatic breast cancer study are interwoven with issues in Biomarker and Metastasis, Circulating tumor cell.
His research in Surgery intersects with topics in Placebo, Clinical trial and Breast disease.
His most cited work include:
- Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer (997 citations)
- Large-scale genotyping identifies 41 new loci associated with breast cancer risk (834 citations)
- Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer (735 citations)
What are the main themes of his work throughout his whole career to date?
Andreas Schneeweiss mostly deals with Internal medicine, Oncology, Breast cancer, Chemotherapy and Metastatic breast cancer.
Internal medicine is often connected to Surgery in his work.
His Oncology study combines topics in areas such as Pertuzumab, Triple-negative breast cancer, Anthracycline and Pathology.
His work deals with themes such as Gynecology and Clinical trial, which intersect with Breast cancer.
His Chemotherapy research is multidisciplinary, incorporating perspectives in Gastroenterology, Regimen and Adjuvant.
His Metastatic breast cancer research incorporates themes from Cancer research, Progression-free survival, Primary tumor, Metastasis and Bevacizumab.
He most often published in these fields:
- Internal medicine (74.12%)
- Oncology (63.61%)
- Breast cancer (62.26%)
What were the highlights of his more recent work (between 2018-2021)?
- Internal medicine (74.12%)
- Oncology (63.61%)
- Breast cancer (62.26%)
In recent papers he was focusing on the following fields of study:
Andreas Schneeweiss spends much of his time researching Internal medicine, Oncology, Breast cancer, Cancer and Metastatic breast cancer.
His is doing research in Chemotherapy, Trastuzumab, Pertuzumab, Proportional hazards model and Clinical endpoint, both of which are found in Internal medicine.
He studied Chemotherapy and Tolerability that intersect with Carboplatin.
His research integrates issues of Neoadjuvant therapy, Early breast cancer, Atezolizumab, Triple-negative breast cancer and Nab-paclitaxel in his study of Oncology.
Andreas Schneeweiss has researched Breast cancer in several fields, including Hazard ratio, Cancer research, Clinical trial, Circulating tumor cell and Durvalumab.
His work in Metastatic breast cancer tackles topics such as Progression-free survival which are related to areas like Maintenance therapy and Metastasis.
Between 2018 and 2021, his most popular works were:
- A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study (114 citations)
- Abstract GS1-04: IMpassion130: Efficacy in immune biomarker subgroups from the global, randomized, double-blind, placebo-controlled, phase III study of atezolizumab + nab-paclitaxel in patients with treatment-naïve, locally advanced or metastatic triple-negative breast cancer (46 citations)
- Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and Prognosis. (39 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Breast cancer
Andreas Schneeweiss mainly investigates Breast cancer, Internal medicine, Oncology, Clinical trial and Cancer.
His work on Estrogen receptor as part of general Breast cancer research is often related to PARP inhibitor, thus linking different fields of science.
His Estrogen receptor study incorporates themes from Genome-wide association study and Tumor Subtype.
His study in Chemotherapy, Metastatic breast cancer, Odds ratio, Tolerability and Disease falls under the purview of Internal medicine.
The study incorporates disciplines such as Neoadjuvant therapy, Pertuzumab, Trastuzumab, Placebo and Triple-negative breast cancer in addition to Oncology.
His Clinical trial research includes themes of Circulating tumor cell, Prospective cohort study, Randomized controlled trial, Axillary Lymph Node Dissection and Mastectomy.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
